Oak Pharma
ActiveSummary
Oak Pharma has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €78,004 and a net result of €48,250. Equity is growing by about 8.2% per year across the filed financial years. Its solvency ranks better than 24% of 9,770 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
02-07
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
10-07
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
19-07
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
31-12
Financial
Back to profitnet €56,274
Net result €56,274 after one loss-making year.
27-07
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format
2022
31-12
Financial
Weakest financial yearnet -€55,588
Net result drops to -€55,588, the lowest in the series; recovery starts the following year.
20-07
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format
2021
29-07
NBB filing
Annual accounts filed
financial year 2020 · micro format
2020
03-08
NBB filing
Annual accounts filed
financial year 2019 · micro format · 3 days late
2019
09-07
NBB filing
Annual accounts filed
financial year 2018 · micro format
2018
25-07
NBB filing
Annual accounts filed
financial year 2017 · micro format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 4 deeds read
About the unread acts
We know of 4 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.